Company News
Smarter Cancer Targeting: How Bispecific Antibodies Are Rewriting the Rules of Oncology
Bispecific antibodies can convert previously undruggable targets with on-target toxicity into safe therapeutic opportunities, effectively decoupling efficacy from dose-limiting adverse effects.
Cancer-Driven Somatic Mutations Enrich Alzheimer's Disease Brain Microglia-like Macrophages, Driving Neuroinflammation and Neurodegeneration
Alpha Lifetech leverages phage display and peptide library screening platforms to facilitate Alzheimer's disease target discovery and antibody development.
A pH-Tunable Thiourea Bridge Opens New Doors in Cyclic Peptide Drug Discovery
A pH-switchable thiourea cyclization is used for generating structurally diverse cyclic peptide libraries, enabling the discovery of potent and stable binders against challenging protein-protein inter
CD19 CAR-T Therapy Achieves Triple Remission in Refractory Autoimmune Diseases
This article demonstrates that a single infusion of CD19 CAR-T cells can achieve simultaneous, drug-free remission of three refractory autoimmune diseases by resetting the B cell compartment.
Literature Analysis (Science) | Breaking the Central Dogma: The Discovery of Protein-Templated DNA Synthesis
This discovery overturns the Central Dogma by demonstrating that proteins can serve as direct templates for sequence-specific DNA synthesis, fundamentally redefining the flow of genetic information.
Literature Analysis (Nature) | Evo 2 Technical Analysis Decoding the Blueprint of Life with AI
Alpha Lifetech offers specialized CRO services in Phage Display-based Antibody Discovery - including VHH, Fab, scFv, Aptamer, and Peptide development.
SCIENCE Literature Analysis (IF = 45.8) | CAR-A for Alzheimer’s: A Next-Generation Neuro-Immunotherapy Approach
Alpha Lifetech provides high stability, conformation specific molecular entities (including VHH, Fab, and scFv), paired with CRO services from phage display discovery to CAR functional validation.
Literature Analysis (IF = 10.5) | Bridging the Gap in NSCLC Therapy: The Rise of Antibody-Drug Conjugates
Alpha Lifetech provides a comprehensive and fully integrated Antibody Discovery Platform to generate high-affinity, highly specific antibodies, accelerating your ADC development.
Literature Analysis (IF = 21.7) | Unlocking the Black Box: Mechanisms of Resistance in Next-Generation Antibody-Drug Conjugates
India Reports Nipah Virus Outbreak: What is Nipah Virus?
Alpha Lifetech has established a mature and robust Antibody Discovery Platform to accelerate drug discovery pipeline.